Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 44

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 3
Chunk 44
---
 in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. 

Our future profitability may depend, in part, on our ability to commercialize our investigational products in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our investigational products before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our investigational products. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our investigational products, and we cannot predict success in these jurisdictions. If we obtain approval of our investigational products and ultimately commercialize our investigational products in foreign markets, we would be subject to additional risks and uncertainties, including: 

•our customers’ ability to obtain reimbursement for our investigational products in foreign markets; 

•our inability to directly control commercial activities because we are relying on third parties;

•the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; 

•different medical practices and customs in foreign countries affecting acceptance in the marketplace; 

•import or export licensing requirements; 

•longer accounts receivable collection times; 

53

•longer lead times for shipping; 

•language barriers for technical training; 

•reduced protection of intellectual property rights in some foreign countries; 

•the existence of additional potentially relevant third-party intellectual property rights; 

•foreign currency exchange rate fluctuations; and 

•the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. 

Foreign sales of our investigational products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. 

We or the third parties upon which we depend may be adversely affected by earthquakes, fires or other natural disasters. 

Our headquarters and main research facility are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. In addition, fires and other natural disasters may increase in frequency and severity over time due to climate change. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control were to prevent us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of